Scandinavian ChemoTech AB (publ) (CMOTEC-B.ST)
SEK 1.48
(-0.34%)
SEK 1.48
(-0.34%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -21.09 Million SEK | 14.19% |
| 2022 | -24.58 Million SEK | -33.46% |
| 2021 | -18.41 Million SEK | -47.36% |
| 2020 | -12.49 Million SEK | 0.68% |
| 2019 | -12.58 Million SEK | -162.35% |
| 2018 | -4.79 Million SEK | 42.42% |
| 2017 | -8.33 Million SEK | -2.37% |
| 2016 | -8.13 Million SEK | -589.26% |
| 2015 | -1.18 Million SEK | -4096.73% |
| 2014 | -28.13 Thousand SEK | -277.22% |
| 2013 | -7459.00 SEK | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -4.1 Million SEK | -28.13% |
| 2024 Q1 | -3.2 Million SEK | 37.78% |
| 2023 Q2 | -6.38 Million SEK | -24.13% |
| 2023 Q4 | -5.14 Million SEK | -13.74% |
| 2023 FY | -21.09 Million SEK | 14.19% |
| 2023 Q1 | -5.14 Million SEK | 27.7% |
| 2023 Q3 | -4.52 Million SEK | 29.09% |
| 2022 Q2 | -6.39 Million SEK | -20.35% |
| 2022 FY | -24.58 Million SEK | -33.46% |
| 2022 Q4 | -7.11 Million SEK | -0.18% |
| 2022 Q3 | -7.09 Million SEK | -10.96% |
| 2022 Q1 | -5.31 Million SEK | 2.1% |
| 2021 FY | -18.41 Million SEK | -47.36% |
| 2021 Q1 | -2.78 Million SEK | 0.25% |
| 2021 Q2 | -3.79 Million SEK | -36.3% |
| 2021 Q3 | -5.73 Million SEK | -51.0% |
| 2021 Q4 | -5.43 Million SEK | 5.27% |
| 2020 Q2 | -2.55 Million SEK | 26.18% |
| 2020 FY | -12.49 Million SEK | 0.68% |
| 2020 Q3 | -2.85 Million SEK | -11.5% |
| 2020 Q1 | -3.46 Million SEK | 25.71% |
| 2020 Q4 | -2.79 Million SEK | 2.07% |
| 2019 FY | -12.58 Million SEK | -162.35% |
| 2019 Q2 | -2.18 Million SEK | 15.89% |
| 2019 Q4 | -4.66 Million SEK | -62.25% |
| 2019 Q1 | -2.59 Million SEK | -137.18% |
| 2019 Q3 | -2.87 Million SEK | -31.47% |
| 2018 Q3 | -851.3 Thousand SEK | 45.24% |
| 2018 FY | -4.79 Million SEK | 42.42% |
| 2018 Q4 | -1.09 Million SEK | -28.72% |
| 2018 Q2 | -1.55 Million SEK | -20.04% |
| 2018 Q1 | -1.29 Million SEK | 0.0% |
| 2017 Q1 | -2.44 Million SEK | -5.16% |
| 2017 FY | -8.33 Million SEK | -2.37% |
| 2017 Q3 | -2.34 Million SEK | 10.45% |
| 2017 Q2 | -2.61 Million SEK | -7.21% |
| 2016 Q1 | -256 Thousand SEK | 31.74% |
| 2016 FY | -8.13 Million SEK | -589.26% |
| 2016 Q4 | -2.32 Million SEK | -205.49% |
| 2016 Q2 | -453.12 Thousand SEK | -77.0% |
| 2016 Q3 | -759.81 Thousand SEK | -67.68% |
| 2015 Q4 | -375.04 Thousand SEK | -59.02% |
| 2015 Q3 | -235.85 Thousand SEK | 0.0% |
| 2015 FY | -1.18 Million SEK | -4096.73% |
| 2014 FY | -28.13 Thousand SEK | -277.22% |
| 2013 FY | -7459.00 SEK | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AcouSort AB (publ) | -17.08 Million SEK | -23.419% |
| Active Biotech AB (publ) | -45.8 Million SEK | 53.95% |
| Alzinova AB (publ) | -16.48 Million SEK | -27.979% |
| Asarina Pharma AB (publ) | -12.82 Million SEK | -64.414% |
| Alligator Bioscience AB (publ) | -248.58 Million SEK | 91.516% |
| BioArctic AB (publ) | 229.24 Million SEK | 109.2% |
| Calliditas Therapeutics AB (publ) | -466.18 Million SEK | 95.476% |
| Camurus AB (publ) | 431.44 Million SEK | 104.888% |
| Cantargia AB (publ) | -280.02 Million SEK | 92.468% |
| Diamyd Medical AB (publ) | -151.85 Million SEK | 86.111% |
| Guard Therapeutics International AB (publ) | -113.32 Million SEK | 81.389% |
| Kancera AB (publ) | -64.88 Million SEK | 67.497% |
| Karolinska Development AB (publ) | 5.38 Million SEK | 491.589% |
| LIDDS AB (publ) | -40.2 Million SEK | 47.543% |
| Lipum AB (publ) | -37.17 Million SEK | 43.27% |
| Lipigon Pharmaceuticals AB (publ) | -12.12 Million SEK | -73.903% |
| Magle Chemoswed Holding AB (publ) | 12.16 Million SEK | 273.317% |
| Modus Therapeutics Holding AB (publ) | -17.89 Million SEK | -17.847% |
| NextCell Pharma AB | -41.95 Million SEK | 49.735% |
| Saniona AB (publ) | -95.81 Million SEK | 77.987% |
| Simris Alg AB (publ) | -37.3 Million SEK | 43.463% |
| Vicore Pharma Holding AB (publ) | -310.94 Million SEK | 93.217% |
| Elicera Therapeutics AB (publ) | -16.39 Million SEK | -28.62% |
| Xbrane Biopharma AB (publ) | -388.17 Million SEK | 94.567% |
| Xspray Pharma AB (publ) | -179.66 Million SEK | 88.261% |
| Amniotics AB (publ) | -30.87 Million SEK | 31.678% |
| CombiGene AB (publ) | -35.66 Million SEK | 40.864% |
| Genovis AB (publ.) | 61.5 Million SEK | 134.294% |
| Mendus AB (publ) | -101.61 Million SEK | 79.245% |
| Isofol Medical AB (publ) | -37.07 Million SEK | 43.106% |
| OncoZenge AB (publ) | -15.9 Million SEK | -32.631% |
| Xintela AB (publ) | -54.08 Million SEK | 61.003% |
| Ziccum AB (publ) | -21.41 Million SEK | 1.499% |
| Intervacc AB (publ) | -102.85 Million SEK | 79.494% |
| Sprint Bioscience AB (publ) | -438 Thousand SEK | -4715.297% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -16.52 Million SEK | -27.646% |
| Corline Biomedical AB | -1.8 Million SEK | -1065.893% |
| IRLAB Therapeutics AB (publ) | -177.83 Million SEK | 88.14% |
| Bio-Works Technologies AB (publ) | -56.82 Million SEK | 62.882% |
| Aptahem AB (publ) | -11.11 Million SEK | -89.789% |
| Infant Bacterial Therapeutics AB (publ) | -123.06 Million SEK | 82.862% |
| Fluicell AB (publ) | -26.55 Million SEK | 20.573% |
| Biovica International AB (publ) | -124.82 Million SEK | 83.103% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 50.049% |
| Abliva AB (publ) | -95.5 Million SEK | 77.917% |
| Egetis Therapeutics AB (publ) | -326.9 Million SEK | 93.548% |
| 2cureX AB (publ) | -32.51 Million SEK | 35.141% |
| I-Tech AB | 20.2 Million SEK | 204.395% |
| Hansa Biopharma AB (publ) | -831.72 Million SEK | 97.464% |
| Cyxone AB (publ) | -22.98 Million SEK | 8.256% |
| ExpreS2ion Biotech Holding AB (publ) | -91.4 Million SEK | 76.925% |
| Biosergen AB | -27.03 Million SEK | 21.992% |
| Nanologica AB (publ) | -75.15 Million SEK | 71.937% |
| SynAct Pharma AB | -215.81 Million SEK | 90.227% |
| Annexin Pharmaceuticals AB (publ) | -44.05 Million SEK | 52.125% |
| BioInvent International AB (publ) | -330.3 Million SEK | 93.615% |
| Stayble Therapeutics AB (publ) | -23.73 Million SEK | 11.147% |
| Oncopeptides AB (publ) | -249.11 Million SEK | 91.533% |
| Pila Pharma AB (publ) | -9.93 Million SEK | -112.397% |
| Ascelia Pharma AB (publ) | -109.28 Million SEK | 80.701% |
| Diagonal Bio AB (publ) | -11.67 Million SEK | -80.605% |